Project Status

Development Status

Transparency about our development stage and the path forward.

Preclinical Development

Anaxa is currently in a preclinical development phase. The biomarker concept has been defined, and preliminary data demonstrate differences between sarcoidosis patients and control groups.

A patent application has been filed to protect the intellectual property around our diagnostic approach.

Current activities focus on further data validation and assay development to prepare for clinical validation studies.

Milestones Achieved

Biomarker concept defined

Patient cohort analysis ongoing

Preliminary data demonstrating association

Multi-platform validation (bead-based assays, ELISA)

Patent application filed

Ongoing data validation

Assay development

Clinical validation studies

Looking Ahead

Development Roadmap

Our path from research discovery to clinical application.

Phase 1

Discovery

Completed

•Biomarker identification
•Initial validation
•Patent filing

Phase 2

Development

Current

•Assay optimization
•Data validation
•Protocol development

Phase 3

Clinical Validation

Planned

•Clinical studies
•Performance evaluation
•Regulatory preparation

Phase 4

Implementation

Future

•Regulatory approval
•Manufacturing scale-up
•Clinical adoption

Our Commitment

Development Transparency

As an early-stage life science company, we believe in being transparent about where we are in the development process. We are confident in the scientific foundation of our work, while acknowledging that significant steps remain before a diagnostic product could reach clinical practice.

We are actively seeking partnerships and collaborations to advance our development program and bring this diagnostic approach to patients who need it.

Interested In
Collaborating?

We welcome inquiries from potential partners, investors, and collaborators who share our vision for improving sarcoidosis diagnosis.